Fig. 8.

Inhibition of the NO/sGC pathway attenuates histamine-induced reductions in lymphatic CF and tone. This figure compares the same data from the lymphatics that received pretreatment with L-NAME or ODQ with lymphatics that had no inhibitors applied prior to the addition of 100 μM histamine. (A) The change in CF is shown for 100 μM L-NAME or 100 μM ODQ versus no treatment (left set of bars), and histamine alone versus histamine treatment in the presence of L-NAME or ODQ (right set of bars). (B) The change in tone is shown in response to the same inhibitors before and after histamine treatment. The “no inhibitor” group baseline measurement was taken during a 5-min period ending 20 min before the addition of histamine, and the change from baseline prior to histamine represents a 5-min period just before the addition of histamine. *P<0.05 versus baseline, same group. ^†P<0.05 versus no inhibitor + histamine. N=7 for the “no inhibitor” group and N=6 for the L-NAME and ODQ groups.